ReviewDiagnostics (Basel, Switzerland)2023
Lung Cancer Staging: Imaging and Potential Pitfalls.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Global characterization of extrachromosomal circular DNA in cerebrospinal fluid of lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Computed Tomography Versus Pathologic Tumor Size in Resected Lung Tumors: High Correlation, Limited Agreement, and the Impact of Ground-Glass Opacity.Tomography (Ann Arbor, Mich.) · 2026Article
- Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer.European radiology · 2026Article
- Pulmonary Tuberculosis: The Great Mimicker of Lung Cancer.Clinical case reports · 2026Article
- Factors associated with upstaging in patients with resectable non-small cell lung cancer: a modern institutional sample.Journal of thoracic disease · 2026Article
- Histopathological and Molecular Predictors of the First Site of Dissemination in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Something old something new-introduction to the ninth edition TNM classification of lung cancer.The British journal of radiology · 2025Review
- Benefits fromCancers · 2025Article
- Clinical TNM Lung Cancer Staging: A Diagnostic Algorithm with a Pictorial Review.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- Article
- Novel Semi-Nested Real-Time PCR Assay Leveraging Extendable Blocking Probes for ImprovedBiomolecules · 2024Article
- Article
- Evaluating peritumoral and intratumoral radiomics signatures for predicting lymph node metastasis in surgically resectable non-small cell lung cancer.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer deaths in men and women in the United States. Accurate staging is needed to determine prognosis and devise effective treatment plans. The International Association for the Study of Lung Cancer (IASLC) has made multiple revisions to the tumor, node, metastasis (TNM) staging system used by the Union for International Cancer Control and the American Joint Committee on Cancer to stage lung cancer. The eighth edition of this staging system includes modifications to the T classification with cut points of 1 cm increments in tumor size, grouping of lung cancers associated with partial or complete lung atelectasis or pneumonitis, grouping of tumors with involvement of a main bronchus regardless of distance from the carina, and upstaging of diaphragmatic invasion to T4. The N classification describes the spread to regional lymph nodes and no changes were proposed for TNM-8. In the M classification, metastatic disease is divided into intra- versus extrathoracic metastasis, and single versus multiple metastases. In order to optimize patient outcomes, it is important to understand the nuances of the TNM staging system, the strengths and weaknesses of various imaging modalities used in lung cancer staging, and potential pitfalls in image interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.